These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15620470)

  • 1. Naturally-acquired immunity to Neisseria meningitidis group A.
    Amir J; Louie L; Granoff DM
    Vaccine; 2005 Jan; 23(8):977-83. PubMed ID: 15620470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum group a anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic.
    Ismail AA; Harris SL; Granoff DM
    Pediatr Infect Dis J; 2004 Aug; 23(8):748-55. PubMed ID: 15295225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group A antibody persistence five years after meningococcal polysaccharide vaccination in the Sudan.
    Flitter BA; Ismail A; Vu D; Granoff DM
    Hum Vaccin; 2007; 3(4):135-8. PubMed ID: 17581284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.
    Welsch JA; Granoff D
    Infect Immun; 2004 Oct; 72(10):5903-9. PubMed ID: 15385492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine.
    Harris SL; King WJ; Ferris W; Granoff DM
    Infect Immun; 2003 Jan; 71(1):275-86. PubMed ID: 12496177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparity in functional activity between serum anticapsular antibodies induced in adults by immunization with an investigational group A and C Neisseria meningitidis-diphtheria toxoid conjugate vaccine and by a polysaccharide vaccine.
    Harris SL; Finn A; Granoff DM
    Infect Immun; 2003 Jun; 71(6):3402-8. PubMed ID: 12761124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine.
    Granoff DM; Morgan A; Welsch JA
    Pediatr Infect Dis J; 2005 Feb; 24(2):132-6. PubMed ID: 15702041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
    Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine.
    Vu DM; Welsch JA; Zuno-Mitchell P; Dela Cruz JV; Granoff DM
    J Infect Dis; 2006 Mar; 193(6):821-8. PubMed ID: 16479517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum factors and polymorphonuclear leukocytes in human host defence against Neisseria meningitidis. Studies of interactions with special reference to a chemiluminometric technique.
    Fredlund H
    Scand J Infect Dis Suppl; 1993; 87():1-72. PubMed ID: 8511525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children.
    Granoff DM; Morgan A; Welsch JA
    Vaccine; 2005 Jul; 23(34):4307-14. PubMed ID: 15921829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.
    Tall H; Yaro S; Kpoda HB; Ouangraoua S; Trotter CL; Njanpop Lafourcade BM; Findlow H; Bai X; Martin C; Nwakamma I; Ouedraogo JB; Gessner BD; Borrow R; Mueller JE
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S540-6. PubMed ID: 26553686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody.
    Welsch JA; Granoff D
    Clin Vaccine Immunol; 2007 Dec; 14(12):1596-602. PubMed ID: 17913865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on the bactericidal antibody against Neisseria meningitidis serogroup C strains after immunization with a divalent polysaccharide (A plus C) vaccine].
    Xu L; Luo LZ; Zhu BQ; He L; Gao Y; Shao ZJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun; 30(6):619-21. PubMed ID: 19957632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avidity of IgG antibodies against meningococcal serogroup a polysaccharide and correlations with bactericidal activity in sera from meningitis patients and controls from Ethiopia.
    Medhane M; Tunheim G; Naess LM; Mihret W; Bedru A; Norheim G; Petros B; Aseffa A; Rosenqvist E
    Scand J Immunol; 2014 Apr; 79(4):267-75. PubMed ID: 24383864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
    Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
    Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
    Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
    Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan.
    Huo Z; Sinha R; McNeela EA; Borrow R; Giemza R; Cosgrove C; Heath PT; Mills KH; Rappuoli R; Griffin GE; Lewis DJ
    Infect Immun; 2005 Dec; 73(12):8256-65. PubMed ID: 16299322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.
    Ceyhan M; Yildirim I; Balmer P; Riley C; Laher G; Andrews N; Borrow R; Kurt N; Turgut M; Aydogan A; Ecevit C; Uysal G; Schultze V
    Vaccine; 2007 Oct; 25(41):7233-7. PubMed ID: 17707957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
    Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
    J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.